Table 2 : Guidelines on the use of TA in clinical practice-evidence-based appraoch.


  German Working Group of Clinical
Nephrology, 2002 [3]
Apheresis Applications Committee of the ASFA, 2010, 2013 [3, 6, 7]

  TA modality Evidence
class
Severity
grade
TA
modality
Category Recommendation grade

RRGN (ANCA associated)
dialysis dependence
DAH
Immune complex
nephritis, dialysis- independence
TPE,
IA-Protein-A,
Peptid-GAM®
I b A TPE I
I
III
1A
1C
2B
Anti-glomerular basement disease (Goodpasture´s syndrome), dialysis- dependent, no DAH
DAH
Dialysis-independent
TPE,
IA-Protein-A,
Peptid-GAM®
II a B TPE III
I
I
2B
1C
1B
Focal segmental GN
(FSGN)
primary
secondary
recurrent (in transplanted kidney)
TPE,
IA-Protein-A,
Peptid-GAM®,
Tryptophan,
Anti-human-Ig
IV
III
---
C
B
---
TPE III
III
I
---
---
IB

Bambauer et al.Clinical Nephrology and Urology Science  2014 1:2DOI : 10.7243/2054-7161-1-2